![[Copy] Eukaryotic mRNA Sequencing-NGS](http://www.bmkgene.com/uploads/%E7%BD%91%E7%AB%99%E4%BA%A7%E5%93%8125.1.14-033.jpg)
The Biological and Industrial Revolution of lncRNA
For decades, the central dogma of molecular biology focused heavily on protein-coding genes. However, modern genomics has revealed that while over 90% of the human genome is actively transcribed, only about 2% code for proteins. The remaining vast transcriptional landscape was once dismissed as "junk DNA" or transcriptional noise. Today, we understand that this region is populated by functional non-coding RNAs, among which Long Non-Coding RNAs (lncRNAs)—defined as transcripts longer than 200 nucleotides without protein-coding potential—play a pivotal role in cellular regulation.
The biological significance of lncRNAs cannot be overstated. They function as molecular scaffolds, decoys, guides, and signals, regulating gene expression at epigenetic, transcriptional, post-transcriptional, and translational levels. Consequently, lncRNA sequencing (lncRNA-Seq) has transitioned from a specialized academic pursuit to a foundational tool in commercial biotechnology, pharmaceutical research, and agricultural development.
Key Insight: lncRNA-Seq enables researchers to profile both known and novel non-coding transcripts, mapping their interactions with chromatin, DNA, protein, and other RNA species. This comprehensive profiling is crucial for identifying key regulatory hubs in disease pathways and agricultural traits.
Deep Application Scenarios of lncRNA Sequencing
1. Oncology & Precision Medicine
In cancer biology, lncRNAs act as both oncogenes and tumor suppressors. Their highly tissue-specific expression patterns make them excellent candidates for liquid biopsy biomarkers. For instance, the lncRNA PCA3 is a well-established urinary biomarker for prostate cancer. By leveraging high-throughput lncRNA sequencing, clinical researchers can discover novel diagnostic and prognostic signatures, leading to more precise patient stratification and personalized treatment regimens.
2. Drug Discovery & Target Identification
Pharmaceutical companies are increasingly targeting lncRNAs using Antisense Oligonucleotides (ASOs), small interfering RNAs (siRNAs), and small molecules. Because lncRNAs fold into complex secondary and tertiary structures, understanding their exact sequence and isoform variation via full-length transcriptomics is critical for molecular docking and drug design. lncRNA-Seq provides the high-resolution structural and sequence mapping required to develop these targeted therapeutics.
3. Agricultural Genomics & Crop Breeding
In agricultural biotechnology, lncRNAs regulate complex biological processes including vernalization, flowering time, photoperiod sensitivity, and stress response. Annotating the non-coding genome of crops and livestock allows breeders to select for traits that enhance drought tolerance, disease resistance, and yield. By performing de novo lncRNA annotation alongside whole-genome sequencing, agricultural scientists can unlock new pathways for gene editing (CRISPR-Cas9) and marker-assisted selection.
4. Single-Cell & Spatial Transcriptomics
The integration of lncRNA-Seq with single-cell RNA sequencing (scRNA-Seq) and spatial transcriptomics represents the cutting edge of genomic research. It allows scientists to visualize where specific regulatory non-coding RNAs are active within a tissue microenvironment. This is particularly vital in neurobiology, where localized lncRNA expression in specific neuronal subtypes governs synaptic plasticity and cognitive functions.
Commercial Landscape and Technological Trends
The global market for transcriptomics is experiencing rapid growth, driven by falling sequencing costs and the rise of multi-omics integration. A key technological trend in this space is the shift from short-read sequencing (Next-Generation Sequencing, NGS) to long-read sequencing (Third-Generation Sequencing, TGS) platforms. While short-read platforms like Illumina NovaSeq are highly cost-effective for quantification, they struggle to resolve full-length lncRNA transcripts due to their highly repetitive sequences and complex alternative splicing events.
Long-read technologies from PacBio (Sequel II) and Oxford Nanopore (PromethION) have revolutionized the field by sequencing intact, single-molecule transcripts from end to end. This eliminates the need for computational transcript assembly, providing unambiguous identification of novel lncRNA isoforms and structural variants. Leading genomic service providers now offer hybrid pipelines that combine the depth of NGS with the accuracy of TGS to deliver unparalleled insights into the non-coding transcriptome.
Content Creation Strategies for Genome Sequencing & lncRNA-Seq
In the highly technical domain of genomics, content creation serves as the bridge between raw bioinformatics data and actionable scientific discovery. Effective content creation in this space is not merely about writing blog posts; it involves the synthesis of complex biological insights into whitepapers, peer-reviewed publications, protocol guides, and interactive data visualization portals. For businesses offering genomic services, high-quality content is a core driver of search engine visibility (SEO) and authority building (E-E-A-T).
To optimize content for search engines while maintaining scientific rigor, content creators must target long-tail keywords that reflect the search intent of researchers, lab managers, and biopharma executives. Topics such as "PacBio vs. Nanopore for full-length transcriptomics," "lncRNA target prediction algorithms," and "automated NGS library preparation pipelines" attract highly qualified traffic. Furthermore, embedding structured data, high-resolution figures, and case studies ensures that the content remains engaging and authoritative.
Biomarker Technologies (BMKGene): Global Genomics Leader
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
Our Advanced Multi-level Platforms
Sequencing Infrastructure
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5, MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI platforms: DNBSEQ-G400, DNBSEQ-T7
Bionano Irys system
Waters XEVO G2-XS QTOF & QTRAP 6500+
State-of-the-Art Facilities
Over 20,000 square feet of advanced molecular laboratories equipped with state-of-the-art biomolecular instruments.
Standardized spaces for sample extraction, library construction, clean rooms, and sequencing labs operating under strict SOPs to ensure the highest data quality.
Bioinformatics & BMKCloud
Our self-developed BMKCloud platform offers a reliable, easy-to-use online bioinformatics analysis environment.
Powered by 4,260 computing cores with peak computing power exceeding 121,708.8 Gflop per second, backed by CPUs with 41,104 memory and 3 PB of total storage capacity.
Fully Automated Platform for Next-generation sequencing -- Brilliant Lab 1000
Biomarker Technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to high-throughput NGS library construction services.
BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, providing our customers with superior, industry-leading sequencing services.
Enterprise Qualifications & Intellectual Properties
Our commitment to scientific excellence is validated by global certifications and an extensive portfolio of patents and software copyrights in transcriptomics and genome assembly.
Patents & Software Copyrights
